Xencor, Inc. — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications1liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
XmAb541The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on participants' tumor outcomes.	Cancer	Phase 1	À vérifier	United States	À vérifier
XmAb808The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on participants' tumor outcomes.	Cancer	Phase 1	À vérifier	United States	À vérifier
XmAb541The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on participants' tumor outcomes.	Cancer	Phase 1	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
XmAb541	Cancer	Phase 1	NCT07593092	Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors	RECRUITING

Publications

1

Molécule	Indication / population	Titre	Journal	Date
XmAb808		A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies.	Molecular cancer therapeutics